相似文献
1
NICE appraisals should be everybody's business.
BMJ. 2007 May 5;334(7600):936-8. doi: 10.1136/bmj.39190.420081.94.
2
NICE: mostly a bad idea.
Emerg Med J. 2009 Sep;26(9):627-8. doi: 10.1136/emj.2009.072132.
3
NICE work--providing guidance to the British National Health Service.
N Engl J Med. 2004 Sep 30;351(14):1383-5. doi: 10.1056/NEJMp048221.
4
Infection control: everybody's business.
Br J Nurs. 2010;19(16):S2. doi: 10.12968/bjon.2010.19.Sup6.78210.
5
The NICE way of influencing health spending: a conversation with Sir Michael Rawlins. Interview by Nicholas Timmins.
Health Aff (Millwood). 2009 Sep-Oct;28(5):1360-5. doi: 10.1377/hlthaff.28.5.1360.
6
From guidance to practice: Why NICE is not enough.
BMJ. 2002 Apr 6;324(7341):842-5. doi: 10.1136/bmj.324.7341.842.
7
NICE and the public health.
Br J Clin Pharmacol. 2004 Dec;58(6):575-80. doi: 10.1111/j.1365-2125.2004.02195.x.
8
NICE is too generous in approving drugs, analysis says.
BMJ. 2015 Feb 19;350:h955. doi: 10.1136/bmj.h955.
9
Rationing new medicines in the UK.
BMJ. 2009 Jan 22;338:a3182. doi: 10.1136/bmj.a3182.
10
Drug assessment: UK style.
Drug Ther Bull. 2013 Dec;51(12):141-4. doi: 10.1136/dtb.2013.12.0225.
引用本文的文献
1
Demands for 'off-licence' access to trastuzumab (Herceptin): content analysis of UK newspaper articles.
Health Expect. 2011 Mar;14(1):38-47. doi: 10.1111/j.1369-7625.2010.00617.x.
2
From rationing to rational: the evolving status of NICE.
J R Soc Med. 2008 Sep;101(9):436-42. doi: 10.1258/jrsm.2008.080167.
3
Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.
Pharmacoeconomics. 2008;26(7):537-50. doi: 10.2165/00019053-200826070-00001.
4
Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies.
Pharmacoeconomics. 2008;26(2):91-8. doi: 10.2165/00019053-200826020-00001.
5
Rationing in the NHS.
BMJ. 2007 May 26;334(7603):1068-9. doi: 10.1136/bmj.39218.599109.80.
本文引用的文献
1
New treatments for neovascular acute macular degeneration.
BMJ. 2007 Feb 10;334(7588):269-70. doi: 10.1136/bmj.39100.460671.BE.
2
How much will Herceptin really cost?
BMJ. 2006 Nov 25;333(7578):1118-20. doi: 10.1136/bmj.39008.624051.BE.
3
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
N Engl J Med. 2006 Feb 23;354(8):809-20. doi: 10.1056/NEJMoa053028.
4
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
N Engl J Med. 2005 Oct 20;353(16):1673-84. doi: 10.1056/NEJMoa052122.
5
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
N Engl J Med. 2005 Oct 20;353(16):1659-72. doi: 10.1056/NEJMoa052306.
Zotero 插件